Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.54 |
| ▸ | NOS3 | P29474 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590668 | 0.98 | NOS2 (0.56) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL29813012 | 0.84 | NOS2 (0.41) | NOS2NOS3 | |
| SCHEMBL21603570 | 0.79 | NOS2 (0.54) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL20621321 | 0.79 | NOS2 (0.48) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL28576724 | 0.79 | NOS2 (0.48) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL15740563 | 0.78 | NOS3 (0.37) | NOS2NOS3LMNANOS1KDM4E | |
| SCHEMBL28559228 | 0.77 | NOS2 (0.47) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL28576663 | 0.77 | NOS2 (0.47) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL28559227 | 0.77 | NOS2 (0.47) | NOS2NOS3LMNACCR1CCR5 | |
| SCHEMBL9777733 | 0.77 | NOS3 (0.35) | NOS2NOS3NOS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4268898-A2 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220002298-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3802537-A1 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002298-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NOS2 4848/4885NOS3 4865/4885LMNA 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.